Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome.
19
COVID
metabolic-associated fatty liver disease
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
26
08
2021
accepted:
06
01
2022
entrez:
11
2
2022
pubmed:
12
2
2022
medline:
12
2
2022
Statut:
epublish
Résumé
A proposal has recently been advanced to change the traditional definition of nonalcoholic fatty liver disease to metabolic-associated fatty liver disease (MAFLD), to reflect the cluster of metabolic abnormalities that may be more closely associated with cardiovascular risk. Long coronavirus disease 2019 (COVID-19) is a smoldering inflammatory condition, characterized by several symptom clusters. This study aims to determine the prevalence of MAFLD in patients with postacute COVID syndrome (PACS) and its association with other PACS-cluster phenotypes. We included 235 patients observed at a single university outpatient clinic. The diagnosis of PACS was based on ≥1 cluster of symptoms: respiratory, neurocognitive, musculoskeletal, psychological, sensory, and dermatological. The outcome was prevalence of MAFLD detected by transient elastography during the first postdischarge follow-up outpatient visit. The prevalence of MAFLD at the time of hospital admission was calculated retrospectively using the hepatic steatosis index. Of 235 patients, 162 (69%) were men (median age 61). The prevalence of MAFLD was 55.3% at follow-up and 37.3% on admission ( Metabolic-associated fatty liver disease was highly prevalent after hospital discharge and may represent a specific PACS-cluster phenotype, with potential long-term metabolic and cardiovascular health implications.
Sections du résumé
BACKGROUND
BACKGROUND
A proposal has recently been advanced to change the traditional definition of nonalcoholic fatty liver disease to metabolic-associated fatty liver disease (MAFLD), to reflect the cluster of metabolic abnormalities that may be more closely associated with cardiovascular risk. Long coronavirus disease 2019 (COVID-19) is a smoldering inflammatory condition, characterized by several symptom clusters. This study aims to determine the prevalence of MAFLD in patients with postacute COVID syndrome (PACS) and its association with other PACS-cluster phenotypes.
METHODS
METHODS
We included 235 patients observed at a single university outpatient clinic. The diagnosis of PACS was based on ≥1 cluster of symptoms: respiratory, neurocognitive, musculoskeletal, psychological, sensory, and dermatological. The outcome was prevalence of MAFLD detected by transient elastography during the first postdischarge follow-up outpatient visit. The prevalence of MAFLD at the time of hospital admission was calculated retrospectively using the hepatic steatosis index.
RESULTS
RESULTS
Of 235 patients, 162 (69%) were men (median age 61). The prevalence of MAFLD was 55.3% at follow-up and 37.3% on admission (
CONCLUSIONS
CONCLUSIONS
Metabolic-associated fatty liver disease was highly prevalent after hospital discharge and may represent a specific PACS-cluster phenotype, with potential long-term metabolic and cardiovascular health implications.
Identifiants
pubmed: 35146047
doi: 10.1093/ofid/ofac003
pii: ofac003
pmc: PMC8826155
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac003Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Gastroenterology. 2019 Sep;157(3):590-593
pubmed: 31158374
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Front Endocrinol (Lausanne). 2021 Mar 08;12:604100
pubmed: 33763027
Clin Rev Allergy Immunol. 2021 Feb 20;:
pubmed: 33609255
Adv Ther. 2021 May;38(5):2130-2158
pubmed: 33829368
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Arch Toxicol. 2021 Jul;95(7):2235-2253
pubmed: 34027561
J Intensive Care. 2018 Aug 24;6:53
pubmed: 30155260
J Clin Med. 2021 Jan 31;10(3):
pubmed: 33572544
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Hepatology. 2019 Oct;70(4):1457-1469
pubmed: 30924946
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
JAMA. 2010 Oct 27;304(16):1833-4
pubmed: 20978262
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Nat Metab. 2021 Jun;3(6):774-785
pubmed: 34035524
Shock. 2021 Jun 1;55(6):723-741
pubmed: 33021569
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Thorax. 2021 Apr;76(4):405-407
pubmed: 33273028
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Liver Int. 2018 Nov;38(11):2060-2068
pubmed: 29577560
Diabetes Metab. 2020 Sep;46(4):335-337
pubmed: 32416321
Front Physiol. 2021 May 11;12:667024
pubmed: 34045976
Gut. 2020 Aug;69(8):1545-1547
pubmed: 32414813
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):138-43
pubmed: 16706825
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Hepatology. 2021 Mar;73(3):1194-1198
pubmed: 32544255
J Gastroenterol Hepatol. 2007 Jul;22(7):967-9
pubmed: 17608841
Int J Mol Sci. 2020 Aug 16;21(16):
pubmed: 32824337
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
Ann Intern Med. 2021 May;174(5):723-725
pubmed: 33284676
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
Am J Gastroenterol. 2018 Nov;113(11):1649-1659
pubmed: 29880964
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Curr Obes Rep. 2018 Dec;7(4):276-288
pubmed: 30155850
Nutr Metab Cardiovasc Dis. 2020 Jul 24;30(8):1236-1248
pubmed: 32571616
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937